Sanyou Biopharmaceuticals officially launched STAL (Super-Trillion Antibody Libraries) on June 3, 2022, which is a super-trillion innovative antibody drug discovery platform of Sanyou’s own intellectual property.
Also Read: UnitySC raises EUR 48 million with Jolt Capital, the French Government and Supernova Invest
Sanyou Biopharmaceuticals officially launched STAL (Super-Trillion Antibody Libraries) on June 3, 2022, which is a super-trillion innovative antibody drug discovery platform of Sanyou’s own intellectual property.
Developed by Sanyou after seven years of continuous innovation and independent R&D, STAL represents a significant breakthrough over the previous generation of the sub-trillion innovative antibody discovery platforms. The STAL discovery platform integrates nine categories of super-trillion innovative antibody libraries with the overall library capacity up to 10 trillion. The screening validations with dozens of targets showed that thousands of innovative lead antibodies can be discovered via the STAL platform, and the quantity is dozens or even hundreds of times that of canonical methods.
Hundreds of millions of patients worldwide are suffering from cancer, autoimmune diseases, allergic diseases and metabolic diseases every year. Drugs including monoclonal antibody, bispecific antibody, ADC, AOC, RAC, PDC and CAR-T therapy are the mainstream treatments for these diseases. More than 100 of biological drugs have been approved with total annual market revenue approaching $200 billion. Antibodies with high specificities are the common core components of these drugs and play an important role in precise targeting.
The STAL discovery platform integrates technologies of phage display and mammalian cell expression, and is supplemented with fully automated screening and integrated antibody drug R&D platforms. The STAL is effective for challenging innovative targets and development of highly difficult drug modalities. It can meet the R&D needs related to the discovery of various innovative biological drugs, including fully human antibodies, humanized single domain antibodies, humanized monoclonal antibodies, bispecific antibodies, multi-specific antibodies, polypeptides, ADC, PDC and miniaturized proteins. The obtained candidates have natural conformations, high affinity and high developability.
The STAL discovery platform is underpinned by a client-oriented, modular, diversified, and customized business system, which is not only applicable to the R&D of various innovative biological drugs, but also to the research of disease mechanisms and development of the diagnostic products. Dozens of projects from the platform have delivered the pre-clinical candidates, several projects have completed the pre-clinical R&D and entered the clinical phase.